Sila Realty Trust, Inc. · Real Estate · REIT - Healthcare Facilities
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$30.24
−$0.00 (−0.02%) 3:58 PM ET
After hours$30.23
−$0.00 (−0.02%) 4:49 AM ET
Prev closePrevC$30.24
OpenOpen$30.25
Day highHigh$30.26
Day lowLow$30.22
VolumeVol475,539
Avg volAvgVol1,162,800
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.67B
P/E ratio
45.13
FY Revenue
$200.71M
EPS
0.67
Gross Margin
88.28%
Sector
Real Estate
AI report sections
MIXED
SILA
Sila Realty Trust, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+16% (Above avg)
Vol/Avg: 1.16×
RSI
72.25(Overbought)
Overbought (>70)
0255075100
MACD momentum
Intraday
-0.00 (Weak)
MACD: -0.00 Signal: -0.00
Short-Term
-0.23 (Weak)
MACD: 0.53 Signal: 0.76
Long-Term
-0.17 (Weak)
MACD: 1.47 Signal: 1.64
Intraday trend score
47.00
LOW39.00HIGH62.00
Latest news
SILA•8 articles•Positive: 2Neutral: 1Negative: 5
NegativeGlobeNewswire Inc.• Brodsky & Smith
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.
KALVTHRSILALSTAmerger investigationfiduciary dutyshareholder litigationfair value
Sentiment note
Under investigation for potential breach of fiduciary duties regarding fair process and fair value in $30.38 per share all-cash acquisition by Blue Owl Capital affiliates
NegativeGlobeNewswire Inc.• Halper Sadeh Llc
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Sila Realty Trust's sale to Blue Owl affiliates, Esperion Therapeutics' sale to ARCHIMED funds, and a merger between Corebridge Financial and Equitable Holdings. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
Company is under investigation for potential securities law violations and breach of fiduciary duties related to its sale at $30.38 per share, with concerns that insiders may receive disproportionate benefits.
NegativeGlobeNewswire Inc.• Brodsky & Smith
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)
Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisition at $30.38/share), Lisata Therapeutics (Kuva Labs acquisition at $4.00/share plus CVRs), and SkyWater Technology (IonQ acquisition at $35.00/share).
ESPRSILALSTASKYTmerger investigationfiduciary dutyfair valueshareholder rights
Sentiment note
Under investigation for potential breach of fiduciary duties regarding fair process and fair value in $2.4 billion acquisition by Blue Owl Capital affiliates
NegativeGlobeNewswire Inc.• Halper Sadeh Llc
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating Sila Realty Trust's $30.38 per share sale to Blue Owl Real Estate Capital affiliates and Lisata Therapeutics' $4.00 per share sale to Kuva Labs. The firm is examining potential securities law violations and breaches of fiduciary duties, seeking to determine if shareholders are receiving fair consideration and if insider benefits are being prioritized over ordinary shareholder interests.
Company is under investigation for potential securities law violations and breach of fiduciary duties related to its acquisition. The investigation suggests shareholders may not be receiving fair consideration and insiders may be receiving preferential treatment.
NegativeGlobeNewswire Inc.• Juan Monteverde
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
Class action law firm Monteverde & Associates PC announced investigations into several merger and acquisition transactions, including Lisata Therapeutics' sale to Smithfield Foods, Independent Bank Corporation's merger with HCB Financial Corp, and Sila Realty Trust's sale to Sunshine Ultimate Parent LLC. The firm is seeking shareholders who may have concerns about these proposed deals.
LSTAIBCPHCBNSILAclass actionmerger and acquisitionshareholder investigationsecurities litigation
Sentiment note
Class action investigation into sale to Sunshine Ultimate Parent LLC, indicating potential shareholder concerns about transaction fairness or valuation
PositiveBenzinga• Lekha Gupta
Sila Realty Trust Agrees To Buyout At 19% Market Premium
Sila Realty Trust has agreed to be acquired by Blue Owl Capital Inc. affiliates in a $2.4 billion deal at $30.38 per share, representing a 19% premium to the closing price on April 17, 2026. The acquisition is unanimously approved by Sila's board and expected to close in Q2 or Q3 2026, pending shareholder approval. Post-closure, Sila will delist from the NYSE.
SILAOWLacquisitionbuyoutM&Apremiumreal estateREIT
Sentiment note
The company is being acquired at a 19% premium to the closing price and 25.6% premium to the 30-day VWAP, representing a favorable exit for shareholders. Stock surged 19.17% on the acquisition announcement, indicating strong investor approval.
NeutralGlobeNewswire Inc.• Reged
RegEd Honored with Multiple SILA Award Nominations, Showcasing Industry Leadership in Licensing and Compliance
RegEd received multiple nominations from the Securities & Insurance Licensing Association (SILA), including two individual nominations for compliance experts and an Organization of the Year Award nomination, highlighting the company's leadership in insurance and securities compliance technology.
Mentioned as the awarding organization providing professional recognition and networking opportunities
PositiveInvesting.com• Brett Owens
Healthcare Is Sickly but These Dividend Yields up to 7% May Still Have a Pulse
Healthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges.
Relatively new REIT with strong financial security, decent total return, and stable property portfolio
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal